For Immediate Release 9 February 2007 BioProgress plc Completion of licensing agreement with Uluru on novel Oradisc(TM) product for the treatment of mouth ulcers and mouth pain in Europe London, UK, 9 February 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the speciality pharma and healthcare company, has today announced that it has completed a licensing agreement with Uluru Inc, for a specific product for the treatment of mouth ulcers using Uluru's Oradisc(TM) technology. The product agreement is in addition to the current anti-emetic product already in development between the two parties. The product is being positioned within BioProgress's strategy of patient supportive care, especially with painful conditions of the mouth such as that seen when patients are undergoing oncology treatment. The product is expected to be available both as a prescription medicine and as an Over the Counter medicine. BioProgress will be marketing the product within the European, CIS and Middle East regions. The product will be applied for market approval within the second half of 2007. The current market in the UK alone is £28.8m (IRI/PAGB 2005). It is expected that BioProgress will develop a broad, product-based franchise in the area of sore mouth conditions - a major area of unmet need. It plans to be the leading dominant player within the EU and Middle East Regions with a focus on using soluble polymer technology, whether in film or as liquid. BioProgress will pay an initial milestone payment of $600,000 for the exclusive rights to the product with further milestones based upon regulatory and sales based milestones. Steve Martin, Chief Development Officer, BioProgress, said: "BioProgress is pleased that the relationship with Uluru is delivering products to add to our growing portfolio. It is important that the Company is able to gain a critical mass within the area of sore mouth conditions, ranging from xerostomia (dry mouth), mucositis (inflammation of the mucous membranes) to mouth ulcerations. The area has a broad market in that products can be used as prescription medicines, Over the Counter Medicines and importantly into the dental arena. This also enhances brands such as Collunovar which were previous purchased within Dexo France. Having a broad commercialisation strategy enables BioProgress to maximise rapid revenues from the projects. With an enhanced regulatory team and increases in our operational management we are pleased that such partnerships will enhance the current strategy of BioProgress." For further information: BioProgress Plc + 44 (0) 20 7098 9881 Richard Trevillion, CEO Steve Martin, CDO Hiral Patel, CFO Buchanan Communications + 44 (0) 20 7466 5000 Rebecca Skye Dietrich/Mark Court About BioProgress BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL(TM) polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to www.bioprogress.com Forward-Looking Information. The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company"s filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions. ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology. This information is provided by RNS The company news service from the London Stock Exchange
Cambridgeshire -- (MARKET WIRE) -- February 9, 2007 --